{"filing":{"accession_number":"0001213900-26-094408","cik":"0001075880","ticker":"KZIA","company_name":"KAZIA THERAPEUTICS LTD","form":"6-K","filing_date":"2026-08-27","report_date":"2026-08-27","primary_document":"ea0303684-6k_kazia.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1075880/000121390026094408/ea0303684-6k_kazia.htm"},"events":[{"id":30091,"run_id":27576,"accession_number":"0001213900-26-094408","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"Kazia announced positive clinical trial results for paxalisib in advanced triple-negative breast cancer, reporting a 100% clinical benefit rate (83% objective response rate) in six evaluable patients with durable complete metabolic response and favorable safety profile, representing material clinical progress on the company's lead program.","company_name":"KAZIA THERAPEUTICS LTD","ticker":"KZIA","filing_date":"2026-08-27","form":"6-K","submitted_at":null,"items":[{"id":32594,"accession_number":"0001213900-26-094408","item_number":"EX-99.1","item_title":"ea030368401ex99-1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"This is a clinical trial results announcement for Kazia's lead asset paxalisib in advanced triple-negative breast cancer, reporting a 100% clinical benefit rate (83% objective response rate) in six evaluable patients with durable complete metabolic response, favorable safety profile, and translational biomarker improvements. While technically a clinical milestone rather than financial earnings, this represents material clinical progress on the company's lead program that would significantly affect investor assessment of the registrant's pipeline value and development trajectory. The announcement is structured as a press release disclosing material clinical data, analogous to how biotech companies report interim trial results as discrete material events.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-27T20:38:50.920860+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":30092,"run_id":27576,"accession_number":"0001213900-26-094408","anchor_item_number":"EX-99.2","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.65,"summary":"Kazia furnished a confidential investor presentation dated August 27, 2026, in connection with a proposed equity offering (registration statement File No. 333-294392), disclosing clinical trial data, pipeline information, and financial position including approximately $46 million in cash and runway to 2029.","company_name":"KAZIA THERAPEUTICS LTD","ticker":"KZIA","filing_date":"2026-08-27","form":"6-K","submitted_at":null,"items":[{"id":32595,"accession_number":"0001213900-26-094408","item_number":"EX-99.2","item_title":"ea030368401ex99-2.htm","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"This is a confidential investor presentation dated August 27, 2026, prepared in connection with a proposed equity offering (registration statement File No. 333-294392). The presentation discloses clinical trial data, pipeline information, and financial position (approximately $46 million cash, runway to 2029), but is fundamentally a capital-raising document rather than a discrete material event. While the clinical data and financial runway are material to investors, the exhibit itself is a marketing/disclosure document for an equity offering that does not fit neatly into standard 8-K event categories. The domain is financial (capital raising) but the specific event type is ambiguous—it is neither a debt issuance, dilutive equity issuance announcement, nor a periodic report, but rather a prospectus-related disclosure supporting an offering.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-27T20:38:50.920860+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32594,"accession_number":"0001213900-26-094408","item_number":"EX-99.1","item_title":"ea030368401ex99-1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"This is a clinical trial results announcement for Kazia's lead asset paxalisib in advanced triple-negative breast cancer, reporting a 100% clinical benefit rate (83% objective response rate) in six evaluable patients with durable complete metabolic response, favorable safety profile, and translational biomarker improvements. While technically a clinical milestone rather than financial earnings, this represents material clinical progress on the company's lead program that would significantly affect investor assessment of the registrant's pipeline value and development trajectory. The announcement is structured as a press release disclosing material clinical data, analogous to how biotech companies report interim trial results as discrete material events.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-27T20:38:50.920860+00:00","company_name":"KAZIA THERAPEUTICS LTD","ticker":"KZIA","filing_date":"2026-08-27"},{"id":32595,"accession_number":"0001213900-26-094408","item_number":"EX-99.2","item_title":"ea030368401ex99-2.htm","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"This is a confidential investor presentation dated August 27, 2026, prepared in connection with a proposed equity offering (registration statement File No. 333-294392). The presentation discloses clinical trial data, pipeline information, and financial position (approximately $46 million cash, runway to 2029), but is fundamentally a capital-raising document rather than a discrete material event. While the clinical data and financial runway are material to investors, the exhibit itself is a marketing/disclosure document for an equity offering that does not fit neatly into standard 8-K event categories. The domain is financial (capital raising) but the specific event type is ambiguous—it is neither a debt issuance, dilutive equity issuance announcement, nor a periodic report, but rather a prospectus-related disclosure supporting an offering.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-27T20:38:50.920860+00:00","company_name":"KAZIA THERAPEUTICS LTD","ticker":"KZIA","filing_date":"2026-08-27"}]}